Calidi Biotherapeutics Company Description
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, develops allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses in the United States.
Its product pipeline comprises CLD-101, which is in Phase 1b/2 clinical trial for the treatment of high-grade glioma, and Phase 1, dose-escalation clinical trial for NNV1 in patients with newly diagnosed high-grade gliomas; CLD-201 product for solid tumors, such as breast cancer, head and neck squamous cell carcinoma, and soft tissue sarcoma, which is in pre-clinical studies; CLD-301) for multiple indications in preclinical studies; and CLD-400 for certain lung cancer and metastatic solid tumors.
The company also offers NeuroNova, an oncolytic virus platform; and SuperNova platform. Calidi Biotherapeutics, Inc. is headquartered in San Diego, California.
| Country | United States |
| Industry | Biological Products, Except Diagnostic Substances |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Eric Poma |
Contact Details
Address: 4475 Executive Drive San Diego, Delaware 92121 United States | |
| Phone | 858 794 9600 |
| Website | calidibio.com |
Stock Details
| Ticker Symbol | CLDWW |
| Exchange | OTCMKTS |
| Stock Type | Warrants |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Allan J. Camaisa | Chief Executive Officer and Chairman of the Board |
| Wendy Pizarro Campbell Esq. | Chief Legal, Chief Corporate Dev, Chief Diversity, Chief Admin Officer and Corp Secretary and Director |
| Dr. Boris Minev M.D., Ph.D. | President of Medical and Scientific Affairs and Interim Chief Medical Officer |
| Andrew C. Jackson | Chief Financial Officer |